Clinical Trial Update: Anrotinib and Tirelizumab in First-line Treatment of RM-NPC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial exploring anrotinib and tirelizumab as first-line treatment for nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Anrotinib (anrotinib)
• Tirelizumab (tirelizumab)

Snippet

Sponsor: Zhongshan People's Hospital, Guangdong, China | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: UNKNOWN